https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-12-12 / Front Immunol 2022;13:1080947
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-12-12 / Front Immunol 2022;13:10809472022-12-12 00:00:002022-12-12 00:00:00Derivation and external validation of dendritic cell-related gene signatures for predicting prognosis and immunotherapy efficacy in bladder urothelial carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-09-18 / Curr Oncol 2022 Sep;29(9):6700-6713
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-09-18 / Curr Oncol 2022 Sep;29(9):6700-67132022-09-18 00:00:002022-09-27 14:47:20Immunogenic Cell Death Role in Urothelial Cancer Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-07-30 / J Clin Transl Res 2021 Aug;7(4):485-500
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-07-30 / J Clin Transl Res 2021 Aug;7(4):485-5002021-07-30 00:00:002021-07-30 00:00:00Immune escape mechanisms and immunotherapy of urothelial bladder cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-09 / Vaccines (Basel) 2021 Jun;9(6)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-09 / Vaccines (Basel) 2021 Jun;9(6)2021-06-09 00:00:002021-06-09 00:00:00Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-27 / BMC Cancer 2021 May;21(1):625
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-27 / BMC Cancer 2021 May;21(1):6252021-05-27 00:00:002021-05-27 00:00:00Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-03-10 / Int J Mol Sci 2021 Mar;22(6)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-03-10 / Int J Mol Sci 2021 Mar;22(6)2021-03-10 00:00:002021-03-10 00:00:00Cell Therapies in Bladder Cancer Management
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-27 / Expert Opin Biol Ther 2020 03;20(3):253-262
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-27 / Expert Opin Biol Ther 2020 03;20(3):253-2622020-01-27 00:00:002020-01-27 00:00:00Novel immunotherapy combinations for genitourinary cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-01 / J Clin Oncol 37, 2019 (suppl; abstr 2639)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-01 / J Clin Oncol 37, 2019 (suppl; abstr 2639)2019-06-01 00:00:002019-06-01 00:00:00Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-05-30 / Ther Apher Dial 2018 Jun;22(3):266-277
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-05-30 / Ther Apher Dial 2018 Jun;22(3):266-2772018-05-30 00:00:002019-02-15 08:48:15Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-10-19 / Eur Urol Focus 2018 04;4(3):442-454
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-10-19 / Eur Urol Focus 2018 04;4(3):442-4542017-10-19 00:00:002022-09-27 09:05:10Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature
